-
1
-
-
85021327019
-
-
U. S. Food and Drug Administration. FDA-Approved HIV Medicines. 2016 accessed November 1, 2016
-
U. S. Food and Drug Administration. FDA-Approved HIV Medicines. 2016; Available at: https://aidsinfo. nih. gov/education-materials/factsheets/ 21/58/fda-approved-hiv-medicines. Accessed November 1, 2016.
-
-
-
-
2
-
-
84958181577
-
Safety of oral tenofovir disoproxil fumaratebased pre-exposure prophylaxis for HIV prevention
-
Mugwanya KK, Baeten JM. Safety of oral tenofovir disoproxil fumaratebased pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf. 2016;15:265-273.
-
(2016)
Expert Opin Drug Saf.
, vol.15
, pp. 265-273
-
-
Mugwanya, K.K.1
Baeten, J.M.2
-
3
-
-
84944712010
-
HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans
-
Spinner CD, Boesecke C, Zink A, et al. HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151-158.
-
(2016)
Infection.
, vol.44
, pp. 151-158
-
-
Spinner, C.D.1
Boesecke, C.2
Zink, A.3
-
4
-
-
84965013459
-
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
-
Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30: 1973-1983.
-
(2016)
AIDS
, vol.30
, pp. 1973-1983
-
-
Fonner, V.A.1
Dalglish, S.L.2
Kennedy, C.E.3
-
5
-
-
84868153362
-
-
U. S. Food and Drug Administration, http://www. fda. gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210. htm. Accessed November 1, 2016
-
U. S. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at: https://wayback. Archive-it. org/7993/20170112032741/http://www. fda. gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210. htm. Accessed November 1, 2016.
-
FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection.
-
-
-
7
-
-
85021369412
-
-
Center for Diseases Control, accessed November 1, 2016
-
Center for Diseases Control. New guidelines recommend daily HIV prevention pill for those at substantial risk. 2014; 67. Available at: http:// www. cdc. gov/nchhstp/newsroom/2014/PrEP-Guidelines-Press-Release. html. Accessed November 1, 2016.
-
(2014)
New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk
, vol.67
-
-
-
8
-
-
84948822953
-
On-demand preexposure prophylaxis in men at high risk for HIV-1 infection
-
Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
-
(2015)
N Engl J Med.
, vol.373
, pp. 2237-2246
-
-
Molina, J.M.1
Capitant, C.2
Spire, B.3
-
9
-
-
78650549662
-
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
-
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
-
(2010)
N Engl J Med.
, vol.363
, pp. 2587-2599
-
-
Grant, R.M.1
Lama, J.R.2
Anderson, P.L.3
-
10
-
-
84864507852
-
Preexposure prophylaxis for HIV infection among African women
-
Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
-
(2012)
N Engl J Med.
, vol.367
, pp. 411-422
-
-
Van Damme, L.1
Corneli, A.2
Ahmed, K.3
-
11
-
-
84916230041
-
Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa
-
van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3 suppl 2):19146.
-
(2014)
J Int AIDS Soc.
, vol.17
, Issue.3
, pp. 19146
-
-
Van Der Straten, A.1
Stadler, J.2
Luecke, E.3
-
12
-
-
84950248860
-
Should we fear resistance from tenofovir/ emtricitabine preexposure prophylaxis
-
Parikh UM, Mellors JW. Should we fear resistance from tenofovir/ emtricitabine preexposure prophylaxis Curr Opin HIV AIDS. 2016;11: 49-55.
-
(2016)
Curr Opin HIV AIDS.
, vol.11
, pp. 49-55
-
-
Parikh, U.M.1
Mellors, J.W.2
-
13
-
-
85017411079
-
HPTN 067/ADAPT background and methods and Cape Town results
-
February 23-26, Seattle, WA. Asbtract 978LB
-
Bekker LG, Hughes J, Amico KR, et al. HPTN 067/ADAPT background and methods and Cape Town results. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Asbtract 978LB.
-
(2015)
Conference on Retroviruses and Opportunistic Infections
-
-
Bekker, L.G.1
Hughes, J.2
Amico, K.R.3
-
15
-
-
84991401066
-
A comparison of daily and nondaily preexposure prophylaxis dosing in Thai men who have sex with men, Bangkok
-
July 19-22, Vancouver, Canada. Abstract MOAC0306LB
-
Holtz TH, Chitwarakorn A, Curlin ME, et al. A comparison of daily and nondaily preexposure prophylaxis dosing in Thai men who have sex with men, Bangkok. Paper presented at: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 19-22, 2015; Vancouver, Canada. Abstract MOAC0306LB.
-
(2015)
8th IAS Conference on HIV Pathogenesis Treatment and Prevention
-
-
Holtz, T.H.1
Chitwarakorn, A.2
Curlin, M.E.3
-
16
-
-
81055124999
-
Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention trials network 052 trial
-
Eshleman SH, Hudelson SE, Redd AD, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention trials network 052 trial. J Infect Dis. 2011;204:1918-1926.
-
(2011)
J Infect Dis.
, vol.204
, pp. 1918-1926
-
-
Eshleman, S.H.1
Hudelson, S.E.2
Redd, A.D.3
-
17
-
-
34247110127
-
-
Stanford University, accessed November 3, 2016
-
Stanford University. HIV drug resistance database. 2016; Available at: https://hivdb. stanford. edu. Accessed November 3, 2016.
-
(2016)
HIV Drug Resistance Database
-
-
-
18
-
-
84886705161
-
Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue
-
Louissaint NA, Cao YJ, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013; 29:1443-1450.
-
(2013)
AIDS Res Hum Retroviruses.
, vol.29
, pp. 1443-1450
-
-
Louissaint, N.A.1
Cao, Y.J.2
Skipper, P.L.3
-
19
-
-
79960043515
-
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection
-
Bushman LR, Kiser JJ, Rower JE, et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390-401.
-
(2011)
J Pharm Biomed Anal.
, vol.56
, pp. 390-401
-
-
Bushman, L.R.1
Kiser, J.J.2
Rower, J.E.3
-
20
-
-
84954149594
-
Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)
-
Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32:32-43.
-
(2016)
AIDS Res Hum Retroviruses.
, vol.32
, pp. 32-43
-
-
Hendrix, C.W.1
Andrade, A.2
Bumpus, N.N.3
-
21
-
-
84961388620
-
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabinetriphosphate from erythrocytes using dried blood spots
-
Zheng JH, Rower C, McAllister K, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabinetriphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16-20.
-
(2016)
J Pharm Biomed Anal.
, vol.122
, pp. 16-20
-
-
Zheng, J.H.1
Rower, C.2
McAllister, K.3
-
22
-
-
84919495524
-
Streamlining HIV testing for HIV preexposure prophylaxis
-
Guanira JV, Leigler T, Kallas E, et al. Streamlining HIV testing for HIV preexposure prophylaxis. J Clin Microbiol. 2015;53:179-183.
-
(2015)
J Clin Microbiol.
, vol.53
, pp. 179-183
-
-
Guanira, J.V.1
Leigler, T.2
Kallas, E.3
-
23
-
-
80051549164
-
Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis
-
Curtis KA, Kennedy MS, Luckay A, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2011;57:355-362.
-
(2011)
J Acquir Immune Defic Syndr.
, vol.57
, pp. 355-362
-
-
Curtis, K.A.1
Kennedy, M.S.2
Luckay, A.3
-
24
-
-
85021371248
-
The effect of oral pre-exposure prophylaxis on the progression of HIV-1 seroconversion
-
October 17-21, Chicago, IL. Abstract OA03. 01
-
Donnell D, Ramos EM, Baeten J, et al. The effect of oral pre-exposure prophylaxis on the progression of HIV-1 seroconversion. Paper presented at: HIV Research for Prevention; October 17-21, 2016; Chicago, IL. Abstract OA03. 01.
-
(2016)
HIV Research for Prevention
-
-
Donnell, D.1
Ramos, E.M.2
Baeten, J.3
-
25
-
-
84943327425
-
Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis
-
Laeyendecker O, Redd AD, Nason M, et al. Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis. J Infect Dis. 2015;212:754-759.
-
(2015)
J Infect Dis.
, vol.212
, pp. 754-759
-
-
Laeyendecker, O.1
Redd, A.D.2
Nason, M.3
-
26
-
-
84927551045
-
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women
-
Grant RM, Liegler T, Defechereux P, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29:331-337.
-
(2015)
AIDS
, vol.29
, pp. 331-337
-
-
Grant, R.M.1
Liegler, T.2
Defechereux, P.3
-
27
-
-
84880070553
-
Cross-sectional HIV incidence estimation in HIV prevention research
-
Brookmeyer R, Laeyendecker O, Donnell D, et al. Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr. 2013;63(suppl 2):S233-S239.
-
(2013)
J Acquir Immune Defic Syndr.
, vol.63
, pp. S233-S239
-
-
Brookmeyer, R.1
Laeyendecker, O.2
Donnell, D.3
|